Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 31

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
 event of a termination of the contractual relationship between the Company and the entitled employee, options could have been deemed forfeited by MoonLake AG if certain conditions were met. The awards featured an accelerated vesting condition linked to a “Change of Control”, defined as any transfer of shares that resulted in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) would have been deemed fully vested. 

25

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

ESOPNumber of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 202598,3931.505,1806.73Awards exercised for the six months ended June 30, 2025(93,347)1.30Awards forfeited for the six months ended June 30, 2025(5,046)5.25Awards outstanding as of June 30, 2025————Awards exercisable as of June 30, 2025————MoonLake Immunotherapeutics 2022 Equity Incentive PlanOn April 5, 2022 (the “Effective Date”), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.Equity Incentive Plan (Options)Number of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 2025972,476$24.